Xvivo Perfusion (XVIVO.ST)

← Tillbaka till ranking

Xvivo Perfusion

XVIVO.ST OMXS Healthcare

AVVAKTA

54/100

Rank 39 av 289

240.20 SEK -2.28% idag

Kursutveckling (180 dagar)

XVIVO.ST OMX30 (normaliserad)

Kursutveckling vs OMX30

1 dag

-2.28%

-0.9% vs OMX30

1 vecka

+6.28%

+3.6% vs OMX30

1 månad

+36.63%

+40.4% vs OMX30

3 månader

+27.70%

+24.1% vs OMX30

6 månader

+39.65%

+27.5% vs OMX30

Fundamentala nyckeltal

P/E (trailing) 304.1

P/E (forward) 40.6

P/B 3.6

P/S 9.3

EV/EBITDA 53.4

Vinsttillväxt -12.8%

Oms. tillväxt -0.6%

Vinstmarginal 3.1%

Rörelsemarginal 16.3%

ROE 1.2%

ROA 2.3%

Skuld/EK 6%

Likviditetskvot 5.76

Börsvärde 7.6B

Analytikerkonsensus

STRONG_BUY Riktkurs: 302 SEK (5 analytiker)

AI-analys

Teknisk 12.5

Sentiment 0.0

Total 54.4

Risk MEDEL

Kort sikt (3 månader)

55/100

Baserat enbart på tekniska signaler.

Lång sikt (3 år)

52/100

Baserat enbart på sentiment, inga fundamenta tillgängliga.

Övergripande motivering

Fallback: teknisk=12, sentiment=0. AI-analys ej tillgänglig.

Nyckelfaktorer

AI-analys misslyckades

Senaste nyheter

yahoo_finance 2026-01-11

How The Narrative Around Xvivo Perfusion (OM:XVIVO) Is Shifting After The Latest Analyst Upgrade

The latest tweak to fair value and what it signals The fair value estimate for Xvivo Perfusion has been trimmed slightly from SEK 319.6 to SEK 317.6, with a modestly higher discount rate and a small r...

yahoo_finance 2025-12-04

What New Catalysts Are Reshaping the Narrative for Xvivo Perfusion?

Xvivo Perfusion’s latest rating upgrade comes with a refreshed narrative rather than a fundamental shift in its intrinsic value, with the fair value estimate holding steady at SEK 319.6 while the form...

yahoo_finance 2025-11-19

Why The Narrative Around Xvivo Perfusion Is Shifting With Recent Analyst Developments

Xvivo Perfusion’s stock price target has recently been reaffirmed at SEK 319.6 following the latest analyst review, with a slight increase in the discount rate to 5.77 percent. Revenue growth projecti...

yahoo_finance 2025-10-08

How Recent Developments Are Shaping the Xvivo Perfusion Growth Story

Xvivo Perfusion’s Fair Value Estimate has recently been revised downward from SEK 345.6 to SEK 322.6. This reflects a modest adjustment in analysts’ price targets. The revision also comes with a sligh...

Visa på Avanza Yahoo Finance